5 completed, 2 unknown. 7 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 5, Unknown 2 |
| Phase 2 | 1 | Completed 1 |
Follow Transplantation: new trials by email Literature Review of Transplantation trials Research Report on Transplantation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT PD-1 Inhibitor Tislelizumab maintenance therapy - Lymphoma, Large B-Cell, Diffuse, Transplantation | Phase 3 | Unknown | Ruijin Hospital | 94 | 2021-07-09 | 2021-11-22 |
| PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT PD-1 Inhibitor Tislelizumab maintenance therapy - Lymphoma, Large B-Cell, Diffuse, Transplantation | Phase 3 | Unknown | Ruijin Hospital | 132 | 2021-04-01 | 2021-03-16 |
| Donor Simvastatin Treatment in Organ Transplantation Simvastatin 80mg, Control Rx - Heart Failure, Respiratory Failure | Phase 2 / Phase 3 | Completed | Helsinki University Central Hospital | 84 | 2010-06-01 | 2017-09-19 |
| A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma). Generic = Plerixafor - Lymphoma (Non-Hodgkin's Lymphoma), Hodgkin's Disease or Multiple Myeloma | Phase 3 | Completed | Genzyme, a Sanofi Company | 118 | 2008-09-01 | 2015-03-24 |
| Conversion Study From Cyclosporine to FK506MR Based Immunosuppression in Kidney Transplant Subjects tacrolimus - Transplantation | Phase 3 | Completed | Astellas Pharma Inc | 346 | 2007-04-01 | 2014-07-18 |
| A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Liver Recipients Tacrolimus - Transplantation | Phase 3 | Completed | Astellas Pharma Inc | 112 | 2006-10-01 | 2014-07-09 |
| A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Kidney Recipients Tacrolimus - Transplantation | Phase 3 | Completed | Astellas Pharma Inc | 128 | 2006-10-01 | 2014-07-09 |
Lymphoma, Large B-Cell, Diffuse (2) · Heart Failure (1) · Hodgkin Disease (1) · Liver Failure (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Rejection, Psychology (1) · Renal Insufficiency (1) · Reperfusion Injury (1) · Respiratory Insufficiency (1)
Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Cardiovascular Diseases (2) · Lymphoma (2) · Lymphoma, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Vascular Diseases (2) · Behavior (1) · Blood Protein Disorders (1) · Digestive System Diseases (1)
Tacrolimus (3) · Simvastatin (1) · Tin Fluorides (1)
Astellas Pharma Inc (3) · Ruijin Hospital (2) · Genzyme, a Sanofi Company (1) · Helsinki University Central Hospital (1)
France (4) · Germany (4) · Spain (4) · Poland (3) · United Kingdom (3) · China (2) · Finland (2) · Italy (2) · Netherlands (2) · Sweden (2) · Austria (1) · Belgium (1) · Czechia (1) · Denmark (1) · Hungary (1)
Karl B Lemstrom, MD, PhD (1) · Weili Zhao, doctor (1)
2008 (1)